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Abstract
Background: Desmoid tumors are benign but locally aggressive non-malignant tumors derived from fibroblasts.
Surgery, chemotherapy, and radiation therapy have been the mainstay of treatment, but recurrence is common and
side effects can result in significant morbidity. In this case series, we highlight our experiences performing
treatments in the thigh, including strategies for optimizing ablation size and safety.
Case presentation: Since December 2014, 14 magnetic resonance-guided focused ultrasound (MRgFUS)
treatments for desmoid tumors were performed at our institution in seven patients. Nine of these treatments were
completed in three patients with large tumors within the posterior thigh.
The first was a 7-year-old boy who had previously been treated with surgical resection, intra-operative radiation,
along with courses of vinblastine/methotrexate and sorafenib. Pretreatment tumor volume was 770 cm3 with 75%
non-enhancing volume following the initial treatment. The first treatment was complicated by a third-degree
far-field skin burn. Enhanced safety measures were developed to protect the far-field skin. The patient had four
subsequent treatments over 14 months, without complication, with non-perfused volume of 85% on current
imaging.
The second patient was a 21-year-old woman who had previously taken sulindac and celecoxib but had no other
therapy. Pretreatment tumor volume was 740 cm3. The lateral decubitus position was used to minimize the amount
of energy through the sciatic nerve. The first treatment resulted in a relatively low non-perfused volume of 30%. A
follow-up treatment resulted in 75–80% ablation of the target.
The third patient was a 14-year-old girl with no prior treatment. Pretreatment tumor volume was approximately
440 cm3. The sciatic nerve was encased by the anteromedial portion of the mass. A lateral decubitus position and
enhanced safety measures were again used. The first treatment resulted in a relatively low non-perfused volume of
30%, likely related to low energies. The second treatment resulted in 70–80% ablation.
Conclusions: MRgFUS is an effective treatment for desmoid tumors of the thigh with a favorable side effect profile,
allowing for repeated treatments if necessary. Ablation size and safety can be improved with far-field coupling
devices, careful patient positioning, and optimized sonication planning.
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Background
Desmoid tumors, also known as aggressive fibromatosis,
are monoclonal proliferations of fibroblasts arising in
muscle and connective tissues. These tumors are rare,
representing 0.03% of all neoplasms with an incidence of
2–4 million per year [1]. They most frequently occur
sporadically in association with mutations of the
beta-catenin gene, but a minority are associated with
hereditary cancer syndromes, such as familial adenoma-
tous polyposis. These tumors can be symptomatic or
asymptomatic as a function of their local mass effect.
Desmoid tumors also have variable clinical courses with
growth, stability, or regression observed among different
patients.
More established therapies for desmoid tumors include
close observation, surgical resection, radiation therapy,
and systemic medical therapy. Surgery, even with negative
margins, can have recurrence rates as high as 50%, and
multiple recurrences following surgery can result in local
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morbidity [2]. Radiation results in tumor control in
approximately 72–76% of adults but is associated with
pain, reduced motion, pathological fractures, and second-
ary malignancies [3]. Systemic medical therapies such as
tamoxifen, nonsteroidal anti-inflammatory drugs, and
cytotoxic chemotherapy demonstrate variable efficacy.
More recently, cryoablation has been used successfully [4].
Magnetic resonance-guided focused ultrasound
(MRgFUS) has emerged as a safe and effective treatment
for control of desmoid tumors [5–7]. The thigh can be a
challenging location where these tumors can become
quite large, often in close proximity to neurovascular
bundles such as the sciatic nerve, posing unique chal-
lenges and risks for treatment of patients with MRgFUS.
In this case series, we highlight our experiences
performing treatments in the thigh, including strategies
for optimizing ablation size and safety.
Case presentations
Case 1
A 7-year-old boy with a history of a biopsy-proven spor-
adic desmoid tumor within the right anterolateral thigh
was referred for MRgFUS therapy. The patient’s tumor
was previously resected with intra-operative radiation
therapy at the time of surgery (12 Gy). Initial recurrence
was identified on imaging 10 months following the sur-
gery. After the initial recurrence, the patient completed
courses of vinblastine/methotrexate (25 doses), with
continued tumor growth, followed by sorafenib, which
was discontinued after a short trial of therapy as the
patient tolerated the medication poorly and developed a
severe widespread dermatitis requiring hospitalization.
The patient’s tumor continued to grow, measuring up to
21.4 × 8.3 × 7.1 cm, approximately 770 cm3, prior to
treatment.
MRgFUS of the tumor within the thigh was performed
under general anesthesia. The patient was positioned in
the right lateral decubitus position on a 3.0T system
(Discovery MR750w, GE Medical Systems, Milwaukee,
WI). MRgFUS was performed with the ExAblate 2000
MRgFUS system with an in-table 1-MHz transducer
(InSightec, Tirat-Carmel, Israel). The procedure was per-
formed with 96 treatment sonications. Total energy per
sonication ranged between 1423 and 2846 J with an
average of 2168 J. Each individual sonication was 20 s
long. Temperature varied between 60 and 85 °C with
each sonication. Postcontrast imaging immediately fol-
lowing the treatment demonstrated 75% non-enhancing
volume (Fig. 1).
However, the patient’s first treatment was complicated
by a third-degree far-field skin burn. This burn occurred
in the region where sound energy was leaving the
patient, as opposed to the near-field skin entry site
which was submerged in a small water bath. On average,
the center of the typical sonication spot was approxi-
mately 3–4 cm away from the region of the burn. The
overall region of the burn measured up to 17 × 10 cm.
The parents deferred skin grafting, and the burn was
treated with silvadene cream. The area healed within
four months following the initial treatment.
Because of the significant non-perfused volume follow-
ing the first treatment and the potential side effects of
alternative therapies, the parents and referring clinicians
referred the patient for additional MRgFUS therapy.
Three enhanced safety measures were developed to re-
duce the likelihood of a burn.
First, MR-compatible fiberoptic probes (Lumasense Inc,
Santa Clara, CA) were used to directly monitor skin
temperature where the far-field beam exited the patient. A
small amount of ultrasound gel was placed between the
skin and the probe. Temperatures that measured pretreat-
ment were typically around 30–31 °C. A temperature rise
of 2–3 °C was noted at the peak of each sonication, with a
temperature return to approximately 0.2 to 0.5 °C above
the baseline temperature by the end of the cooling period.
Theoretically, there is a small risk of heating between the
probe and the skin; however, we did not see clinical
evidence of significant heating in this region.
In addition to the fiberoptic probes, cold plastic water
bags were placed along the far-field skin in order to both
directly cool the skin and serve as a conduit for acoustic
Fig. 1 Axial spoiled gradient echo fat-saturated postcontrast image
immediately following the first MRgFUS treatment in a 7-year-old boy
with large desmoid tumor within the musculature of the thigh. Near
total non-perfused volume (white circle) is seen at this level within the
central portion of the mass, with minimal rim enhancement
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energy to propagate beyond the far-field air-skin inter-
face. The plastic water bags were refrigerated to approxi-
mately 1.6 °C the night before the procedure. No active
cooling mechanism was used to maintain their
temperature during the procedure. Of note, the use of
water bags resulted in a large signal void centrally within
the MR image by confounding the scanner’s autoprescan
function, resulting in overflipping of the spins. This
artifact was corrected by decreasing the transmitter gain
by about 20% in manual prescan.
Finally, in addition to the probes and water bags, treat-
ment team members developed a system of regular skin
checks every 15–20 sonications in order to directly
monitor any changes in the skin.
The patient went on to have four subsequent treat-
ments in the 14 months since the first treatment
(Table 1). While tumor regrowth occurred between
treatments, each successive treatment resulted in pro-
gressively increased non-perfused volume of the tumor,
which measured up to 90% following the patient’s most
recent treatment. Single small subcentimeter blisters
were observed in the far-field following two of these
subsequent treatments, which may represent a small
area where air was trapped since the water bags did not
perfectly conform to the contour of the patient’s skin.
Otherwise, no complication was observed, and these
blisters resolved within the first week following the
treatment.
Case 2
A 21-year-old woman with a history of a biopsy-proven
sporadic desmoid tumor within the posterior left thigh
was referred for MRgFUS therapy. The patient had pre-
viously been treated with sulindac and celexocib therapy;
however, she palpated interval enlargement and in-
creased firmness of the mass while taking these medica-
tions. A repeat MRI was performed demonstrating
interval growth of the mass which measured up to
13.5 cm in maximum dimension, increased from
11.5 cm 1 year prior. Referral was made to radiation on-
cology. However, there was concern for significant left
ovarian radiation exposure and risk of infertility. Referral
was also made to orthopedic oncology. However, the pa-
tient was advised that resection would be associated with
a significant risk of recurrence and damage to the adja-
cent neurovascular structures within the posterior thigh,
including the sciatic nerve.
At this time, the patient was referred for MRgFUS
therapy. The tumor measured up to 24 × 8.6 × 8.5 cm in
maximum dimension with pretreatment volume of ap-
proximately 730 cm3 and was associated with medial
displacement of the sciatic nerve. Her symptoms at this
time included limiting tolerance for sitting and difficulty
with strenuous activities that relied on use of the left
hamstring group.
MRgFUS of the tumor within the thigh was performed
under general anesthesia. The patient was positioned in
the left lateral decubitus position in order to minimize
the risk to the sciatic nerve. MRgFUS was performed
with the same MRgFUS system. Because despite the
rapid growth of her tumor, the patient was relatively
high-functioning; only the central portion of the tumor
was targeted. The procedure was performed with 38
treatment sonications. Enhanced safety measures were
used as described in case 1. Total energy per sonication
ranged between 1062 and 1911 J with an average of
1539 J. Each individual sonication was 20 s long.
Temperature varied between 52 and 77 °C with each
sonication. Thermal dose volume was 25.7 cm3. Post-
contrast imaging immediately following the treatment
demonstrated a relatively low non-perfused volume of
the central half of the mass, which measured approxi-
mately 30% of the target or 15% of the entire mass
(Table 2). Review of the sonication data revealed that
20/39 treatment sonications did not definitely reach 60 °
C, including 10/39 which did not clearly reach 57 °C
based on the MR thermometry sequences. Overall, the
average temperature was 60.8 °C following each
Table 1 Viable and total tumor volume in the months prior to
and then following several MRgFUS treatments of a large





−5 months 591.8 591.8
−2 months 724.4 724.4
0 months (after first treatment) 771.7 351.6
1 month 704.9 184.7
6 months (after second treatment) 431.9 204.1
8 months 406.8 160.1
10 months (after third treatment) 380.4 197.8
14 months (after fourth treatment) 481.8 70.6 (14.7%)
Following the most recent treatment after 14 months, there was only 14.7%
viable tumor volume, and the overall tumor size had decreased significantly
from the prior treatment
Table 2 Viable and total tumor volume in the months prior to
and then following several MRgFUS treatments of a large





−20 months 454.0 454.0
−2 months 730.7 730.7
0 months (after first treatment) 803.7 694.1
4 months 690.0 678.8
7 months (after second treatment) 789.2 549.6
Treatment effect was greater in the second treatment compared to the first
Bucknor and Rieke Journal of Therapeutic Ultrasound  (2017) 5:4 Page 3 of 6
sonication. Review of the imaging data demonstrated a
subtle fascial band in the soft tissues which potentially
contributed to poor heating during the treatment. Sev-
eral sonications did demonstrate heating accumulating
along this interface.
The patient returned after 6 months for a repeat treat-
ment. The upper half of the tumor was targeted. A slight
obliquity of the left lateral decubitus position was used
in order to shift the location of the previously noted
fascial band. The procedure was performed with the
same treatment setup, and 117 treatment sonications
were performed. Because the procedure tolerated the
first procedure well without any evidence of a skin in-
jury, significantly increased energy was also used com-
pared to the prior treatment with the energy per
sonication ranging between 1474 and 6026 J with an
average of 3861 J. Thermal dose volume measured
74.3 cm3. There was approximately 70% non-enhancing
volume within the targeted superior 1/2 of the mass
(where there had been the most interval growth follow-
ing the prior treatment) (Fig. 2). Interestingly, despite
the increased non-perfused volume, average temperature
was slightly lower in this treatment with an average of
59.0 following each sonication. The patient experienced
no complications following either treatment.
Case 3
The third patient was a 13-year-old girl with a biopsy-
proven sporadic desmoid tumor within the posterior as-
pect of the left thigh. The lesion was initially discovered
by palpation by the patient’s parents, with a rapid
increase in size over the subsequent 2 months. Pretreat-
ment tumor volume was approximately 440 cm3 with di-
mensions of 12.9 × 8.7 × 5.9 cm. The anterior portion of
the tumor circumferentially encased the sciatic nerve
over 9 cm of the length of the nerve. The left lateral de-
cubitus position and enhanced safety measures were
again used as described previously. Sixty-five treatment
sonications were used which ranged in energy between
1790 and 2268 J with an average of 1952 J. Because of
the close relationship with the sciatic nerve, relatively
low energies were used during the first treatment. Ther-
mal dose volume measured 23.9 cm3. There was a rela-
tively low non-perfused volume of approximately 30%
(Table 3). The patient returned after 7 months for repeat
treatment. The procedure was performed with the same
treatment setup, and 140 treatment sonications were
performed. Because the procedure tolerated the first
procedure well without any evidence of a skin injury,
significantly increased energy was also used compared to
Fig. 2 Axial spoiled gradient echo fat-saturated postcontrast image immediately following a second MRgFUS treatment in a 21-year-old woman
with desmoid tumor in the posterior compartment of the thigh. Near total non-perfused volume is seen at this level despite close proximity to
the sciatic nerve (white arrow), with minimal rim enhancement
Table 3 Viable and total tumor volume in the months prior to
and then following several MRgFUS treatments of a large





−3 months 321.8 321.8
0 months (after the first treatment) 381.5 259
3 months 400.7 400.7
6 months (after second treatment) 424.8 121.9
Treatment effect was greater in the second treatment compared to the first
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the prior treatment with the energy per sonication ran-
ging between 1502 and 6094 with an average of 3362 J.
These increased energies resulted in an increased non-
perfused volume of approximately 70% (Fig. 3). The
patient experienced no complications following either
treatment.
Discussion
MRgFUS of desmoid tumors is a promising new indica-
tion for these difficult to treat, locally aggressive neo-
plasms. Treatments of these tumors are safe and
effective, with a recent retrospective study of 15 patients
demonstrating median viable target tumor volume de-
creasing 63% and pain improved to 2.7 from 7.5, on a 1
to 10 Numerical Rating Scale. Skin burn was the most
common complication [5].
However, performing treatments within the thigh can
be challenging, as is the case for other local therapies.
The first case underscores the importance of effective
skin protection in focused ultrasound treatments of the
extremities. While the near-field skin is generally well-
protected by means of a shallow cool water bath within
the table overlying the transducer, the far-field skin is
also at risk. Technically, far-field heating can be difficult
to observe: a single sonication that successfully results in
heating of the target within the desmoid will only allow
minimal sound energy to propagate through toward the
far-field skin. However, there is significant reflection at
the skin-air interface and in large volume sonications, as
is performed for many desmoid tumors; the cumulative
effect can result in significant heating of the far-field
skin. Of note, because this heating is confined to the
very superficial interface composed of a thin dermal
layer, it is very difficult to observe with MR thermometry
or changes in subcutaneous signal intensity. We have
found that the most reliable means of directly observing
the heating is the placement of a fiberoptic temperature
probe along the far-field skin, which provides real time
feedback during the course of the sonication, in addition
to direct observation of the skin at periodic intervals
during the course of treatment.
In terms of skin protection, the use of an acoustic con-
duit is essential to protect the far-field skin for large vol-
ume treatments. Strategies include positioning multiple
water bags and gel pads, which can be pooled before the
treatment, along the far-field skin to provide more direct
thermal protection. Water bags offer the additional ad-
vantage of transparency, allowing for direct visualization
of the skin without significant alterations to the treat-
ment setup.
The second two treatments also highlight the import-
ance of energy selection for desmoid tumors. The major
focused ultrasound systems used to treat desmoid tu-
mors currently rely on software parameters tailored for
treatment of uterine fibroids, and while these tumors
share certain fibrosis promoting features in common,
differences in vascularity and specific monoclonal prolif-
eration (smooth muscle cells in the case of fibroids ver-
sus fibroblasts in the case of desmoids) contribute to
differential acoustic properties which might require
Fig. 3 Sagittal spoiled gradient echo fat-saturated postcontrast images a before and b immediately following MRgFUS treatment in a 14-year-old girl.
The pretreatment image clearly demonstrates the sciatic nerve coursing through the posterior aspect of the mass (black arrows). Post-treatment plane
demonstrates large non-perfused volume with relative sparing of the region immediately adjacent to the nerve (white arrows)
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unique treatment parameters. Future studies aimed at
optimizing treatment parameters for different tumor
types will be important to improving treatment plans
and patient outcomes.
Conclusions
In summary, MRgFUS is an effective treatment for
desmoid tumors within the thigh. Large volume treat-
ments near critical structures are feasible, offering an
important advantage compared to other local therapies.
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